October 4th 2019
Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Expert Recommendations for Pegfilgrastim in Chemotherapy-Induced Febrile Neutropenia
October 25th 2017Researchers developed additional guidance for using granulocyte colony-stimulating factors to optimize pegfilgrastim use in clinical practices for patients at risk of chemotherapy-induced febrile neutropenia.
Read More
Tocilizumab Associated With Higher Risk of Neutropenia Among Biologic DMARDs
October 20th 2017History of neutropenia with methotrexate, concurrent treatment with synthetic disease-modifying antirheumatic drugs (sDMARDs), and tocilizumab were risk factors for developing neutropenia while on biologic DMARDs (bDMARDs), according to a study published in The Journal of Rheumatology.
Read More
The Case for Eliminating the Neutropenic Diet
October 18th 2017Although there is no scientific evidence that a specific diet reduces risk of infection in patients experiencing neutropenia, it is a common strategy in cancer care. Research presented at the 42nd Annual Congress of the Oncology Nursing Society determined that the popular neutropenic diet can be eliminated from practice.
Read More
Diagnosing and Treating Neutropenia: Q&A With Dr Daniel J. DeAngelo
October 13th 2017Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.
Read More
Preventing Infection in Patients With Neutropenia: Q&A With Dr Ruben A. Mesa
October 2nd 2017Individuals who develop neutropenia are at higher risk of infection, and they should understand the symptoms to look for that might mean they need to seek urgent medical care, explained Ruben A. Mesa, MD, of the Mayo Clinic.
Read More
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
July 21st 2017After switching studies, research in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar, according to results presented at the 2017 Annual Meeting of the American Society of Clinical Oncology.
Read More
Transitions of Care in Patients With Cancer
Pharmacists play an integral role in enhancing transitions of care in patients undergoing cancer treatment through medication reconciliation, education, and post-discharge follow-up to ensure optimal, safe, and effective medication use.
Read More
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 4th 2017A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.
Read More
How to Create Successful Alternative Payment Models in Oncology
April 17th 2017By identifying ways to improve cancer care and then designing alternative payment models (APMs) to overcome current payment barriers, APMs can enable oncology practices to deliver better care to patients and save money for payers in a way that is financially sustainable for the practices.
Read More
Little Patient Benefit to Using G-CSF to Prevent Neutropenia
November 21st 2016There is little patient benefit to using granulocyte colony-stimulating factor (G-CSF) to help white blood cell growth and reduce the risk of infection in women with breast cancer, according to a study published in Journal of Clinical Oncology.
Read More
Estimating the Social Value of G-CSF Therapies in the United States
Granulocyte-colony stimulating factors (G-CSFs) reduce the risk of febrile neutropenia in patients with cancer. This study evaluates the clinical and nonclinical value associated with G-CSFs.
Read More
Safety, Efficacy of Balugrastim to Treat Chemotherapy-Induced Neutropenia
July 12th 2016Researchers assessed balugrastim’s efficacy, safety, and tolerability in 4 different clinical trials and found it to be a suitable alternative to pegfilgrastim in regard to reducing the mean duration of severe neutropenia.
Read More
Hypertension Medication Caused Rare Case of Severe Neutropenia in Patient
July 11th 2016In an unusual case, a patient was diagnosed with febrile neutropenia after starting benazepril, an angiotensin-converting enzyme inhibitor. The treatment is rarely associated with agranulocytosis, which is defined as severe neutropenia.
Read More